@VistaPResearch wrote a nice, short piece on Atossa's COVID-19 developments. 

https://t.co/3GucAbqOrv

Like $ALT, $ATOS is also developing their own nasal spray candidate to address COVID-19. If $ALT can reach $20+ , then so can $ATOS down the line. #StockMarket #stocks #invest https://t.co/zesGnzp2SS